Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer
- 399 Downloads
Overexpression of the androgen receptor (AR) and anti-apoptotic genes including X-linked inhibitor of apoptosis protein (XIAP) provide tumors with a proliferative advantage. Therefore, our objective was to determine whether novel antiandrogen (CBDIV17) and XIAP inhibitor based combination therapy can treat advanced prostate cancer.
CBDIV17 and embelin-6g were synthesized and their effect on cell proliferation, apoptosis, cell cycle and AR and XIAP gene silencing determined.
CBDIV17 was more potent than bicalutamide and inhibited proliferation of C4-2 and LNCaP cells, IC50 for CBDIV17 was ∼12 μM and ∼21 μM in LNCaP and C4-2 cells, respectively, whereas bicalutamide had IC50 of ∼46 μM in LNCaP cells and minimal effect in C4-2 cells. CBDIV17 induced apoptosis more effectively compared to bicalutamide and significantly inhibited DNA replication. Combination of CBDIV17 and embelin resulted in supra-additive antiproliferative and apoptotic effects. Embelin downregulated AR expression and decreased androgen-mediated AR phosphorylation at Ser81. These hydrophobic drugs were solubilized using micelles prepared with polyethylene glycol-b-poly (carbonate-co-lactide) (PEG-b-p(CB-co-LA)) copolymer. Combination therapy inhibited prostate tumor growth more effectively compared to control or monotherapy in vivo.
Our results demonstrated that CBDIV17 in combination with embelin can potentially treat advanced prostate cancer.
KEY WORDSandrogen receptor antiandrogen bicalutamide embelin polymeric micelles prostate cancer XIAP
ACKNOWLEDGMENTS & DISCLOSURES
This work is supported by an Idea Award (W81XWH-10-1-0969) from the Department of Defense Prostate Cancer Research Program. We would also like to thank Dr. Liguo Song for his help in obtaining HRMS data. Molecular weight measurement was performed at the Mass Spectrometry Center of the Department of Chemistry at the University of Tennessee at Knoxville using a JEOL (Peabody, MA) AccuTOF-D time-of-flight (TOF) mass spectrometer with a DART (direct analysis in real time) ionization source.
- 5.Goktasand S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol. 1999;26:162–73.Google Scholar
- 12.Li F, Danquah M, Singh S, Wu H, Mahato RI. Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. Drug Deliv Transl Res. 2011;1:240–8.Google Scholar
- 27.Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J, et al. Overview of Taxol safety. J Natl Cancer Inst Monogr. 1993;131–9.Google Scholar